Yang Luo

Dr. Yang Luo

orcid

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2016 in Trends in Biotechnology
Verified
Journal Article
Closed access
Xiang YangXiang Yang
Xiang Yang
XZXiang Zhao
Xiang Zhao
KYKe Yang
Ke Yang
YLYueping Liu
Yueping Liu
YLYu Liu
Yu Liu
YLYang Luo
Yang Luo

15 February 2016 in Journal of the American Chemical Society
Verified
Journal Article
Closed access
XZXuefeng Zou
Xuefeng Zou
LZLi Zhang
Li Zhang
ZWZhaojun Wang
Zhaojun Wang
YLYang Luo
Yang Luo

24 September 2019 in Nature Communications
Verified
Journal Article
Open access
PDF file
GQGuangchao Qing
Guangchao Qing
XZXianxian Zhao
Xianxian Zhao
NGNingqiang Gong
Ningqiang Gong
JCJing Chen
Jing Chen
XLXianlei Li
Xianlei Li
XLXingjie Liang
Xingjie Liang
New strategies with high antimicrobial efficacy against multidrug-resistant bacteria are urgently desired. Herein, we describe a smart triple-functional nanostructure, namely TRIDENT (Thermo-Responsive-Inspired Drug-Delivery Nano-Transporter), for reliable bacterial eradication. The robust antibacterial effectiveness is attributed to the integrated fluorescence monitoring and synergistic chemo-photothermal killing. We notice that temperature rises generated by near-infrared irradiation did not only melt the nanotransporter via a phase change mechanism, but also irreversibly damaged bacterial membranes to facilitate imipenem permeation, thus interfering with cell wall biosynthesis and eventually leading to rapid bacterial death. Both in vitro and in vivo evidence demonstrate that even low doses of imipenem-encapsulated TRIDENT could eradicate clinical methicillin-resistant Staphylococcus aureus, whereas imipenem alone had limited effect. Due to rapid recovery of infected sites and good biosafety we envision a universal antimicrobial platform to fight against multidrug-resistant or extremely drug-resistant bacteria.

26 December 2019 in Analytical Chemistry
Verified
Journal Article
Closed access
RWRuixuan Wang
Ruixuan Wang
XZXianxian Zhao
Xianxian Zhao
XCXiaohui Chen
Xiaohui Chen
XQXiaopei Qiu
Xiaopei Qiu
GQGuangchao Qing
Guangchao Qing
YLYang Luo
Yang Luo

2 January 2020 in Analytical and Bioanalytical Chemistry
Verified
Journal Article
Closed access
PDF file
XZXianxian Zhao
Xianxian Zhao
WZWenqing Zhang
Wenqing Zhang
XQXiaopei Qiu
Xiaopei Qiu
QMQiang Mei
Qiang Mei
YLYang Luo
Yang Luo
WFWeiling Fu
Weiling Fu

28 December 2022 in EBioMedicine
Verified
Journal Article
Open access
HLHeng Li
Heng Li
QHQi-Zhao Huang
Qi-Zhao Huang
HZHong Zhang
Hong Zhang
ZLZhen-Xing Liu
Zhen-Xing Liu
XCXiao-Hui Chen
Xiao-Hui Chen
YLYang Luo
Yang Luo
Human monkeypox is a viral zoonotic smallpox-like disease caused by the monkeypox virus (MPXV) and has become the greatest public health threat in the genus Orthopoxvirus after smallpox was eradicated. The host immune response to MPXV plays an essential role in disease pathogenesis and clinical manifestations. MPXV infection leads to skin lesions with the genital area as the main feature in the current outbreak and triggers a strong immune response that results in sepsis, deep tissue abscess, severe respiratory disease, and injuries to multiple immune organs. Emerging evidence shows that the immunopathogenesis of MPXV infection is closely associated with impaired NK-cell function, lymphopenia, immune evasion, increased antibodies, increased blood monocytes and granulocytes, cytokine storm, inhibition of the host complement system, and antibody-dependent enhancement. In this overview, we discuss the immunopathology and immunopathogenesis of monkeypox to aid the development of novel immunotherapeutic strategies against monkeypox.